Australia’s clinical stage immuno-oncology company, Imugene Limited (ASX:IMU) released its Quarterly 4C Report for the three-month period ended 31st March 2020. The key highlights for the March 2020 quarter include:
- Grant of HER-Vaxx immunotherapy patent in US.
- Completion of PD1-Vaxx GMP manufacturing.
- Completion of PD1-Vaxx preclinical toxicology studies, which confirmed PD1-Vaxx produces high levels of PD1-targeting antibodies.
- New publication on CF33 (Vaxinia) from Professor Yuman Fong.
With research and development expenditure of $2.2 million during the quarter, the Company reported a cash balance of $33.7 million as at 31st March 2020.
IMU traded at $0.023 on 27 April 2020 (12:59 PM AEST).